IL13RA2 and glioblastoma: To improve treatment efficacy, various clinical trials are investigating whether glioblastoma patients would benefit from a combination therapy, either as two immune checkpoint inhibitors or a CAR T cell infusion with neoadjuvant or adjuvant checkpoint blockade.441 Alternatively, multi-antigen targeting cellular immunotherapies are potential solutions for treating cancers with high intra-tumoural heterogeneity.443,444 A clinical trial is currently underway for a dual-antigen T cell therapy targeting both EGFR/EGFRvIII and IL13Ra2 in recurrent glioblastoma (NCT05168423).